MometasoneFormoterol inhalation aerosol: In asthma uncontrolled on medium-or high-dose inhaled corticosteroids

Drugs

Volumn 72, Issue 9, 2012, Pages 1229-1241

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Asthma; Formoterol; Mometasone; Mometasoneformoterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; HYDROCORTISONE; MOMETASONE FUROATE; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; PREGNANE DERIVATIVE;

APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHMA; BINDING AFFINITY; BRONCHITIS; BRONCHODILATING ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPHONIA; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHIBITION KINETICS; LENS DISEASE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MUSCLE SPASM; PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME; TREMOR; UNITED STATES; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; REVIEW;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; METERED DOSE INHALERS; PREGNADIENEDIOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84862116330     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206920-000000000-00000     Document Type: Article

References (29)

1. Fanta CH. Asthma. N Engl J Med 2009; 360 (10): 1002-9
2. World Health Organisation. Asthma fact sheet no. 307 [online]. Available from URL: http://www.who.int/media centre/factsheets/fs307/en/index.html [Accessed 2011 Sep 27]
3. Global Initiative for Asthma. Global burden of asthma[online]. Available from URL: http://www.ginasthma.org/up loads/users/files/backgrounder-20.pdf [Accessed 2010Nov 22]
4. National Heart LaBI. US Department of Health and Human Services. National Asthma Education and Prevention Program. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Summary report 2007 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf [Accessed 2010 Nov 22]
5. Blair R, Breit JS, Peters SP. The Merck Manuals Online Medical Library: asthma [online]. Available from URL: http://www.merckmanuals.com/home/sec04/ ch044/ch044a. html [Accessed 2011 Sep 27]
6. Papiris SA, Manali ED, Kolilekas L, et al. Acute severe asthma: new approaches to assessment and treatment. Drugs 2009; 69 (17): 2363-91
7. Fuhlbrigge AL, Adams RJ, Guilbert W, et al. The burden of asthma in the United States. Am J Resp Crit Care Med 2002; 166: 1044-9
8. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009 Sep; 65 (9): 853-71
9. Postma DS, Kerstjens HA, ten Hacken NH. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedeberg Arch Pharmacol 2008; 378 (2): 203-15
10. Frois C, Wu EQ, Ray S, et al. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 2009 Dec; 31 (12): 2779-803
11. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61 (9): 1325-50 (Pubitemid 32744413)
12. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease. Drugs 1991; 42 (1): 115-37
13. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64 (14): 1597-618 (Pubitemid 38981841)
14. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40: 1227-36
15. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitaryadrenal axis when delivered at high doses. Chest 2000; 118: 1538-46 (Pubitemid 32001774)
16. Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer. Eur J Clin Pharmacol 1999; 55: 131-8 (Pubitemid 29196266)
17. Fan Y, Zhao L, Roy P. NDA22-518: clinical pharmacology review [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/Develop mentResources/UCM224594.pdf [Accessed 2011 Sep 27]
18. Asmanex Twisthaler 110 mcg, 220 mcg (mometasone furoate inhalation powder): US prescribing information. Kenilworth (NJ): Schering Corporation, a subsidiary of Schering-Plough Corporation, 2010
19. Foradil Aerolizer (formoterol fumarate inhalation powder): US prescribing information. Kenilworth (NJ): Schering Corporation, 2002
20. Dulera 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg) inhalation aerosol; Dulera 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol fumarate dihydrate 5 mcg) inhalation aerosol: US prescribing information. Whitehouse (NJ): Schering Corporation, a subsidiary of Merck & Co., Inc., 2010
21. Maspero JF, Nolte H, Cherrez-Ojeda I, et al. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma 2010; 47: 1106-15
22. Weinstein SF, Corren J, Murphy K, et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 mg and 400/10 mg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31 (4): 280-9
23. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 mg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31 (4): 269-79
24. Meltzer EO, Kuna P, Nolte H, et al. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. Epub 2011 Aug 4
25. Weinstein SF, Nathan RA, Nolte H. Combined mometasone furoate/formoterol reduces asthma deteriorations in patients with persistent asthma uncontrolled on mediumor high-dose inhaled corticosteroids [abstract no. P89]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A51-2
26. White M, Meltzer EO, Nathan RA, et al. Improved asthma control with mometasone furoate/formoterol: a new combination treatment for persistent asthma [abstract no. P83]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A49-50
27. Murphy K, Meltzer EO, Nathan RA, et al. Quality of life improvements in persistent asthma subjects receiving combined mometasone furoate and formoterol [abstract no. P88]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A51
28. Nolte H, Maspero J, Cherrez Ojeda I. The safety and tolerability characteristics of mometasone furoate/formoterol (MF/F) combination therapy in patients with persistent asthma: findings from the MF/F phase III clinical development program [abstract no. 275 plus poster]. 75th Annual International ScientificAssembly of theAmerican College of Chest Physicians; 2009 31 Oct-5 Nov; San Diego (CA)
29. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteriods for treating asthma. N Engl J Med 2011 Jun 30; 364 (26): 2473-5